Diabetes mellitus and increased risk of cancer: Focus on metformin and the insulin analogs

Pharmacotherapy

Volumn 30, Issue 11, 2010, Pages 1159-1178

  McFarland, M Shawn ^a   Cripps, Rebecca ^a  

^a Veterans Affairs Tennessee Valley Health Care System   (United States)

Author keywords

Cancer risk; Diabetes; Insulin analogs; Metformin

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; SULFONYLUREA;

BLADDER CANCER; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; ENDOMETRIUM CANCER; HUMAN; LIVER CELL CARCINOMA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; PANCREAS CANCER; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; NEOPLASMS; RISK;

EID: 78149321257     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.11.1159     Document Type: Review

References (65)

1. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of U.S. adults. Am J Epidemiol 2004;159:1160-7.
2. El-Serag H, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80.
3. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 1995;273:1605-9.
4. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005;97:1679-87.
5. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007;50:1365-74.
6. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-23.
7. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007;121:856-62.
8. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007;132:2208-25. (Pubitemid 46693749)
9. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44.
10. Currie CJ, Poole CD, Gale AM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77.
11. Jonasson JM, Ljung R, Tallback M, et al. Insulin glargine use and short-term incidence of malignancies: a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-54.
12. Colhoun H. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish diabetes research network epidemiology group. Diabetologia 2009;52:1755-65.
13. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8. (Pubitemid 44106500)
14. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
15. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer. Diabetes Care 2009;32:1620-5.
16. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use was associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-8.
17. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999;2:307-14.
18. Adami HO, Mclouaghlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
19. Will JC, Galuska DA, Vinicor F, et al. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998;147:816-25.
20. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89: 1360-5. (Pubitemid 27418027)
21. Chow WH, Gridley G, Nyren O, et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995;87:930-1.
22. Calle EE, Murphy TK, Rodriguez C, et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998;9:403-10. (Pubitemid 28466692)
23. Hu FB, Manson JE, Liu S, et al. Prospective study of adult-onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Caner Inst 1999;91:542-7. (Pubitemid 29157063)
24. Smith GD, Egger M, Shipley MJ, et al. Post-challenge glucose concentration, impaired glucose tolerance, diabetes and cancer mortality in men. Am J Epidemiol 1992;136:1110-14. (Pubitemid 23005170)
25. Khaw KT, Wareham N, Bingham S, et al. Preliminary communication: glycated hemoglobin, diabetes and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer - Norfolk study. Cancer Epidemiol Biomarkers Prev 2004;13:915-19.
26. Lee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202. (Pubitemid 40095870)
27. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of U.S. adults. Am J Epidemol 2004;159:1160-7.
28. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. JAMA 1995;273:1605-9.
29. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al. Type II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-83. (Pubitemid 40897433)
30. Chao C, Page J. Type 2 diabetes mellitus and risk of non- Hodgkin lymphoma: a systematic review and meta-analysis. Am J Epidemiol 2008;168:471-80.
31. Mitri J, Castillo J, Pittas AG. Diabetes and risk of non- Hodgkin's lymphoma. Diabetes Care 2008;31:2391-7.
32. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003;35:694-704.
33. Jones J, Clemmons D. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
34. Wei EK, Ma J, Pollak M, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005;14:850-5.
35. Holly JMP, Perks CM. Cancer as an endocrine problem. Best Pract Res Clin Endocrinol Metab 2008;22:539-50.
36. United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
37. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27: 3297-302.
38. Kisfalvi K, Eibl G, Sinnet-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein coupled-receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009;69:2539-45.
39. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110:246-50.
40. Garg SK, Hirsch IB, Skyler JS. Insulin glargine and cancer: an unsubstantiated allegation. Diabetes Technol 2009;8:473-6.
41. Li D, Yeung SJ, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8.
42. Zakikhani M, Dowling R, Fantus LG, Sonenberg N, Pollak M. Metformin is an AMP-kinase dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.
43. Yang YX. Do diabetes drugs modify the risk of pancreatic cancer? Gastroenterology 2009;137:412-30.
44. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;9:1699-708.
45. Sahra IB, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease in cyclin D1 level. Oncogene 2008;27: 3576-86.
46. Kahn BB, Alquier T, Carling D, et al. AMP-activated protein kinase: ancient energy gauge provide clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
47. Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999;35:307-35.
48. Muldaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin - absorption kinetics and action profile compared with regular insulin in healthy nondiabetic subjects. Diabetes Care 1999;22:1501-6.
49. Slieker LJ, Brooke GS, Dimarchi RD, et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than the insulin receptor. Diabetologia 1997;40:S54-61.
50. Hansen BF, Danielsen GM, Drejer K, et al. Sustained signaling from the insulin receptor after stimulation with insulin analoges exhibiting increased mitogenic potency. Biochem J 1996;315:271-9. (Pubitemid 26113562)
51. Novo Nordisk Inc. Novolog (insulin aspart) package insert. Princeton, NJ; 2001.
52. Eli Lilly. Humalog (insulin lispro) package insert. Indianapolis, IN; 2010.
53. sanofi-aventis U.S., LLC. Lantus (insulin glargine) package insert. Bridgewater, NJ; 2007.
54. Novo Nordisk Inc. Levemir (insulin detemir) package insert. Princeton, NJ; 2005.
55. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999-1005. (Pubitemid 30349423)
56. Jorgensen L, Dideriksen L, Drejer K. Carcinogenic effect of human insulin analogue B10Asp in female rats [abstract]. Diabetologia 1992;35(suppl 1):A3.
57. Shukla A, Grisouard J, Ehemann V, et al. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human and mammary epithelial cell lines. Endocr Relat Cancer 2009;16:429-41.
58. Stammberger I, Bube A, Durchfeld-Meyer B, et al. Evaluation of the carcinogenic potential of insulin glargine (Lantus) in rats and mice. Int J Toxicol 2002;21:171-9.
59. Weinstein D, Simon M, Yehezkel E, et al. Insulin analogues display IGF-I mitogenic and anti-apoptotic activities in cultures cancer cells. Diabetes Metab Res Rev 2008;31:1105-11.
60. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008;114:38-44. (Pubitemid 351998750)
61. Rosen M. National health data registers: a Nordic heritage to public health. Scan J Public Health 2002;30:81-5. (Pubitemid 41007498)
62. Rosenstock J, Fonseca V, Mcgill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomized, open-label study. Diabetologia 2009;52:1971-3.
63. Dejgaard A, Lynggaard H, Rastam J, Thomsen MK. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009;52:2507-12.
64. Yang X, Wink K, Ma R, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010;59:1254-60.
65. Mannucci E, Monami M, Balzi D, et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients [published online ahead of print June 14, 2010]. Diabetes Care. Available from http://dx.doi.org/10.2337/dc10-0476.